| 1.17 -0.01 (-0.85%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.54 | 1-year : | 1.78 |
| Resists | First : | 1.32 | Second : | 1.52 |
| Pivot price | 1.24  |
|||
| Supports | First : | 0.99 | Second : | 0.82 |
| MAs | MA(5) : | 1.13 |
MA(20) : | 1.23 |
| MA(100) : | 1.54 |
MA(250) : | 3.26 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.5 |
D(3) : | 26.9 |
| RSI | RSI(14): 43.7 |
|||
| 52-week | High : | 17.2 | Low : | 0.99 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CYTO ] has closed above bottom band by 29.8%. Bollinger Bands are 30.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.21 - 1.21 | 1.21 - 1.22 |
| Low: | 1.1 - 1.11 | 1.11 - 1.12 |
| Close: | 1.16 - 1.17 | 1.17 - 1.18 |
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Wed, 24 Jul 2024
Altamira Therapeutics (NASDAQ:CYTO) Stock Price Down 0.9% - Defense World
Fri, 19 Jul 2024
Altamira Therapeutics Announces Publication of Preclinical Data - WICZ
Tue, 28 May 2024
Altamira Therapeutics boosts RNA nanoparticle stability - Investing.com
Tue, 28 May 2024
Altamira Therapeutics Provides Business Update - GlobeNewswire
Thu, 23 May 2024
What's Going On With Altamira Therapeutics Stock? - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 138 (K) |
| Shares Short P.Month | 129 (K) |
| EPS | -16.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.36 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -52.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.07 |
| PEG Ratio | 0 |
| Price to Book value | 0.26 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|